Three recent studies conducted to examine the role of Takeda Pharmaceutical’s candesartan, the angiotensin receptor blocker (ARB) in the prevention and treatment of diabetic retinopathy have concluded that candesartan is one of the useful treatment options available for the disorder. The research found it to be the first pharmaceutical agent to have improved the patient’s condition in early retinopathy. Candesartan lowered the incidence of retinopathy in both type 1 diabetics (who had not developed it) and improved the condition in type 2 diabetes patients (who had it already).